



MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to *EGFR*, *KRAS*, and *ALK* status

SUPPLEMENTARY MATERIALS



Supplementary Figure 1: Dot plots of microRNA expressions in lung adenocarcinomas according to genetic status (*ALK*-rearranged, *EGFR*-mutated, *KRAS*-mutated, and triple negative).



Supplementary Figure 2: Differential expressions of microRNAs in *EGFR*-mutated lung adenocarcinomas, compared to *KRAS*-mutated lung adenocarcinomas.

Supplementary Table 1: Association between *ALK* rearrangement and E-cadherin expression in lung adenocarcinomas of *EGFR*, *KRAS* and *ALK* groups (n = 52)

	Total N(%)	E-cadherin, N(%)		
		No loss	Loss	<i>p</i> value
ALK	16 (30.8)	6 (37.5)	10(62.5)	0.002*
EGFR+KRAS	36 (69.2)	29(80.6)	7 (19.4)	

* Statistically significant (*p* < 0.05)